Incorporation of pharmacogenetic testing into medication therapy management

被引:35
作者
Haga, Susanne B. [1 ]
Moaddeb, Jivan [1 ]
Mills, Rachel [1 ]
Patel, Mahesh [1 ]
Kraus, William [1 ]
LaPointe, Nancy M. Allen [1 ]
机构
[1] Duke Univ, Sch Med, Ctr Appl Genom & Precis Med, Durham, NC 27710 USA
关键词
medication therapy management; patient satisfaction; pharmacist; pharmacogenetic testing; IMPLEMENTATION CONSORTIUM GUIDELINES; PATIENT SATISFACTION; PHARMACY STUDENTS; CYP2C19; GENOTYPES; CPIC GUIDELINE; EDUCATION; SERVICES; PROGRAM; CYP2D6; RECOMMENDATIONS;
D O I
10.2217/pgs.15.124
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To assess feasibility and patient satisfaction with a pharmacist-delivered medication therapy management (MTM) plus pharmacogenetic (PGx) testing service. Methods: Thirty patients from a cardiology outpatient clinic were enrolled to attend two MTM sessions, undergo PGx testing and complete pre- and post-intervention surveys. Outcome measures included duration of MTM sessions, clinical application of test results, self-reported medication adherence, patient recall of results and perceived value of testing and MTM. Results: Overall, patients were very satisfied with the MTM plus PGx testing service. About half of participants (47%) were able to accurately recall their PGx test results. Comparable to MTM without PGx testing, the first MTM session averaged 40 min and the follow-up MTM session averaged 15 min. Conclusion: PGx testing incorporated into a clinical MTM service offered by pharmacists may be a feasible delivery model and is satisfactory to patients.
引用
收藏
页码:1931 / 1941
页数:11
相关论文
共 52 条
[1]   The WHO UNESCO FIP Pharmacy Education Taskforce [J].
Anderson, Claire ;
Bates, Ian ;
Beck, Diane ;
Brock, Tina Penick ;
Futter, Billy ;
Mercer, Hugo ;
Rouse, Mike ;
Whitmarsh, Sarah ;
Wuliji, Tana ;
Yonemura, Akemi .
HUMAN RESOURCES FOR HEALTH, 2009, 7
[2]   How We Design Feasibility Studies [J].
Bowen, Deborah J. ;
Kreuter, Matthew ;
Spring, Bonnie ;
Cofta-Woerpel, Ludmila ;
Linnan, Laura ;
Weiner, Diane ;
Bakken, Suzanne ;
Kaplan, Cecilia Patrick ;
Squiers, Linda ;
Fabrizio, Cecilia ;
Fernandez, Maria .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2009, 36 (05) :452-457
[3]  
Burmester JK, 2010, METHODS MOL BIOL, V632, P99, DOI 10.1007/978-1-60761-663-4_7
[4]   Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing [J].
Caudle, K. E. ;
Rettie, A. E. ;
Whirl-Carrillo, M. ;
Smith, L. H. ;
Mintzer, S. ;
Lee, M. T. M. ;
Klein, T. E. ;
Callaghan, J. T. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) :542-548
[5]   Recommended Basic Science Foundation Necessary to Prepare Pharmacists to Manage Personalized Pharmacotherapy [J].
Cavallari, Larisa H. ;
Overholser, Brian R. ;
Anderson, Douglas ;
Boyce, Eric ;
Buie, Larry ;
Formea, Christine M. ;
Gallagher, Jason C. ;
Hayney, Mary S. ;
Oestreich, Julie .
PHARMACOTHERAPY, 2010, 30 (06) :626-626
[6]   Evaluation of a pilot medication therapy management project within the North Carolina State Health Plan [J].
Christensen, Dale B. ;
Roth, Mary ;
Trygstad, Troy ;
Byrd, John .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2007, 47 (04) :471-483
[7]  
CMS, LOC COV DET LCD CYP2
[8]  
Cranor Carole W, 2003, J Am Pharm Assoc (Wash), V43, P173, DOI 10.1331/108658003321480713
[9]   Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update [J].
Crews, K. R. ;
Gaedigk, A. ;
Dunnenberger, H. M. ;
Leeder, J. S. ;
Klein, T. E. ;
Caudle, K. E. ;
Haidar, C. E. ;
Shen, D. D. ;
Callaghan, J. T. ;
Sadhasivam, S. ;
Prows, C. A. ;
Kharasch, E. D. ;
Skaar, T. C. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) :376-382
[10]   How well do people recall risk factor test results? Accuracy and bias among cholesterol screening participants [J].
Croyle, Robert T. ;
Loftus, Elizabeth F. ;
Barger, Steven D. ;
Sun, Yi-Chun ;
Hart, Marybeth ;
Gettig, JoAnn .
HEALTH PSYCHOLOGY, 2006, 25 (03) :425-432